{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"Any >/= Grade 3 chemistry laboratory abnormality"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Aspartate aminotransferase (high)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Calcium (low)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Glucose (high)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Potassium (low)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Sodium (low)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Urate (high)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"}],"units":"Participants"}],"description":"Counts of study participants with post-baseline chemistry laboratory abnormalities of Grade 3 or greater per NCI CTCAE version 3.0. Participants with multiple occurrences of a laboratory abnormality within a category are counted once in that category.","groups":[{"description":"Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion","id":"OG000","title":"Brentuximab Vedotin"}],"paramType":"NUMBER","populationDescription":"All participants who received treatment","reportingStatus":"POSTED","timeFrame":"up to 12 months","title":"Chemistry Laboratory Abnormalities >/= Grade 3","type":"SECONDARY","unitOfMeasure":"participants"}